M. Spina et al., Human immunodeficiency virus-related non-Hodgkin lymphoma - Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients, CANCER, 92(1), 2001, pp. 200-206
BACKGROUND. The prognosis of patients with human immunodeficiency virus (HI
V)-related non-Hodgkin lymphoma (NHL) is poor. In fact, despite a high comp
lete response (CR) rate, approximately 50% of these patients die from progr
METHODS. From November 1994 to April 2000, the authors treated 40 patients
with resistant or recurrent HIV-related NHL with a 96-hour continuous intra
venous infusion of cyclophosphamide (187.5 mg/m(2) per day), doxorubicin (1
2.5 mg/m(2) per day), and etoposide (60 mg/m(2) per day).
RESULTS. The median number of cycles administered was two (range, one to si
x cycles). A CR was documented in 4 of 40 patients (10%), and a partial. re
mission (PR) was documented in 7 of 40 patients (18%). The CR median durati
on was 6 months (range, 4-30+ months), whereas PRs lasted for 5 months (ran
ge, 2-8 months). The overall median survival was 4 months (range, < 1-33 mo
nths), and the median survival for responding patients was 10 months.
CONCLUSIONS. The current data confirm that infusional cyclophosphamide, dox
orubicin, and etoposide is active in patients with refractory or recurrent
HIV-related NHL. However, the median survival of these patients remains poo
r, and the other innovative approaches should be used. Cancer 2001;92:200-6
. (C) 2001 American Cancer Society.